FusionNeoAntigen Logo

Home

Download

Statistics

Examples

Help

Contact

Terms of Use

Center for Computational Systems Medicine
leaf

Fusion Gene and Fusion Protein Summary

leaf

Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)

leaf

Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)

leaf

Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)

leaf

Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)

leaf

Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)

leaf

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)

leaf

Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)

leaf

Potential target of CAR-T therapy development

leaf

Information on the samples that have these potential fusion neoantigens

leaf

Fusion Protein Targeting Drugs - (Manual Curation)

leaf

Fusion Protein Related diseases - (Manual Curation)

Fusion Protein:EBF2-YAP1

Fusion Gene and Fusion Protein Summary

check button Fusion gene summary
Fusion partner gene informationFusion gene name: EBF2-YAP1
FusionPDB ID: 24824
FusionGDB2.0 ID: 24824
HgeneTgene
Gene symbol

EBF2

YAP1

Gene ID

64641

10413

Gene nameEBF transcription factor 2Yes1 associated transcriptional regulator
SynonymsCOE2|EBF-2|O/E-3|OE-3COB1|YAP|YAP2|YAP65|YKI
Cytomap

8p21.2

11q22.1

Type of geneprotein-codingprotein-coding
Descriptiontranscription factor COE2Collier, Olf and EBF 2Collier, Olf and EBF transcription factor 2OLF-1/EBF-LIKE 3early B cell factor 2metencephalon-mesencephalnon-olfactory transcription factor 1transcriptional coactivator YAP165 kDa Yes-associated proteinYes associated protein 1protein yorkie homologyes-associated protein 1yes-associated protein 2yes-associated protein YAP65 homologyorkie homolog
Modification date2020031320200329
UniProtAcc

Q9HAK2

Main function of 5'-partner protein: FUNCTION: Transcription factor that, in osteoblasts, activates the decoy receptor for RANKL, TNFRSF11B, which in turn regulates osteoclast differentiation. Acts in synergy with the Wnt-responsive LEF1/CTNNB1 pathway. Recognizes variations of the palindromic sequence 5'-ATTCCCNNGGGAATT-3' (By similarity). {ECO:0000250}.
.
Ensembl transtripts involved in fusion geneENST idsENST00000408929, ENST00000520164, 
ENST00000535548, 
ENST00000528834, 
ENST00000282441, ENST00000345877, 
ENST00000524575, ENST00000526343, 
ENST00000531439, ENST00000537274, 
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)* DoF score1 X 1 X 1=120 X 10 X 13=2600
# samples 121
** MAII scorelog2(1/1*10)=3.32192809488736log2(21/2600*10)=-3.63005039024969
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
Fusion gene context

PubMed: EBF2 [Title/Abstract] AND YAP1 [Title/Abstract] AND fusion [Title/Abstract]

Fusion neoantigen context

PubMed: EBF2 [Title/Abstract] AND YAP1 [Title/Abstract] AND neoantigen [Title/Abstract]

Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)EBF2(25890600)-YAP1(102033186), # samples:1
Anticipated loss of major functional domain due to fusion event.EBF2-YAP1 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
EBF2-YAP1 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
EBF2-YAP1 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
EBF2-YAP1 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
EBF2-YAP1 seems lost the major protein functional domain in Hgene partner, which is a transcription factor due to the frame-shifted ORF.
EBF2-YAP1 seems lost the major protein functional domain in Tgene partner, which is a cell metabolism gene due to the frame-shifted ORF.
EBF2-YAP1 seems lost the major protein functional domain in Tgene partner, which is a tumor suppressor due to the frame-shifted ORF.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID
TgeneYAP1

GO:0006974

cellular response to DNA damage stimulus

18280240

TgeneYAP1

GO:0008283

cell proliferation

17974916

TgeneYAP1

GO:0032570

response to progesterone

16772533

TgeneYAP1

GO:0033148

positive regulation of intracellular estrogen receptor signaling pathway

16772533

TgeneYAP1

GO:0045893

positive regulation of transcription, DNA-templated

20368466

TgeneYAP1

GO:0045944

positive regulation of transcription by RNA polymerase II

25796446

TgeneYAP1

GO:0050767

regulation of neurogenesis

25433207

TgeneYAP1

GO:0050847

progesterone receptor signaling pathway

16772533

TgeneYAP1

GO:0060242

contact inhibition

17974916

TgeneYAP1

GO:0065003

protein-containing complex assembly

20368466

TgeneYAP1

GO:0071480

cellular response to gamma radiation

18280240

TgeneYAP1

GO:0072091

regulation of stem cell proliferation

25433207



check button Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr8:25890600/chr11:102033186)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.
FGviewer

check buttonRetention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

check buttonFusion gene breakpoints across EBF2 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure

check buttonFusion gene breakpoints across YAP1 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure


Top

Fusion Amino Acid Sequences


check buttonFusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)
BP loci
(transcript)
Predicted start
(transcript)
Predicted stop
(transcript)
Seq length
(amino acids)
ENST00000520164EBF2chr825890600-ENST00000526343YAP1chr11102033186+252210895381869443
ENST00000520164EBF2chr825890600-ENST00000282441YAP1chr11102033186+551510895382031497
ENST00000520164EBF2chr825890600-ENST00000537274YAP1chr11102033186+547910895381995485
ENST00000520164EBF2chr825890600-ENST00000345877YAP1chr11102033186+536510895381881447
ENST00000520164EBF2chr825890600-ENST00000531439YAP1chr11102033186+200710895381983481
ENST00000520164EBF2chr825890600-ENST00000524575YAP1chr11102033186+224410895382031497

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score
ENST00000520164ENST00000526343EBF2chr825890600-YAP1chr11102033186+0.0040499280.9959501
ENST00000520164ENST00000282441EBF2chr825890600-YAP1chr11102033186+0.0002904040.99970955
ENST00000520164ENST00000537274EBF2chr825890600-YAP1chr11102033186+0.0002648120.9997352
ENST00000520164ENST00000345877EBF2chr825890600-YAP1chr11102033186+0.0003651760.99963486
ENST00000520164ENST00000531439EBF2chr825890600-YAP1chr11102033186+0.0110092770.98899066
ENST00000520164ENST00000524575EBF2chr825890600-YAP1chr11102033186+0.0104112570.98958874

check button Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for EBF2-YAP1

check button +/-13 AA sequence from the breakpoints of the fusion protein sequences.
HgeneHchrHbpTgeneTchrTbpLength(fusion protein)BP in fusion proteinPeptide
EBF2chr825890600YAP1chr111020331861089183NRNETPSDPVIIDSHIDQTTTWQDPR

Top

Potential FusionNeoAntigen Information of EBF2-YAP1 in HLA I

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
EBF2-YAP1_25890600_102033186.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)
Fusion geneHchrHbpTgeneTchrTbpHLA IFusionNeoAntigen peptideBinding scoreImmunogenic scoreNeoantigen start (at BP 13)Neoantigen end (at BP 13)
EBF2-YAP1chr825890600chr111020331861089HLA-B58:01DSHIDQTTTW0.98290.98271222
EBF2-YAP1chr825890600chr111020331861089HLA-B53:01DSHIDQTTTW0.95870.74281222
EBF2-YAP1chr825890600chr111020331861089HLA-B38:01DSHIDQTTTW0.3230.99141222
EBF2-YAP1chr825890600chr111020331861089HLA-B38:02DSHIDQTTTW0.23520.99081222
EBF2-YAP1chr825890600chr111020331861089HLA-B38:01IDSHIDQTTTW0.81770.98621122
EBF2-YAP1chr825890600chr111020331861089HLA-B38:02IDSHIDQTTTW0.74720.98611122
EBF2-YAP1chr825890600chr111020331861089HLA-B44:06DSHIDQTTTW0.80510.50151222
EBF2-YAP1chr825890600chr111020331861089HLA-A25:01DSHIDQTTTW0.94960.92441222
EBF2-YAP1chr825890600chr111020331861089HLA-B53:02DSHIDQTTTW0.93520.63061222
EBF2-YAP1chr825890600chr111020331861089HLA-B15:13DSHIDQTTTW0.88840.91971222
EBF2-YAP1chr825890600chr111020331861089HLA-B38:05DSHIDQTTTW0.3230.99141222
EBF2-YAP1chr825890600chr111020331861089HLA-B38:05IDSHIDQTTTW0.81770.98621122

Top

Potential FusionNeoAntigen Information of EBF2-YAP1 in HLA II

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
EBF2-YAP1_25890600_102033186.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).
Fusion geneHchrHbpTgeneTchrTbpHLA IIFusionNeoAntigen peptideNeoantigen start (at BP 13)Neoantigen end (at BP 13)
EBF2-YAP1chr825890600chr111020331861089DRB1-0301SDPVIIDSHIDQTTT621
EBF2-YAP1chr825890600chr111020331861089DRB1-0301PSDPVIIDSHIDQTT520
EBF2-YAP1chr825890600chr111020331861089DRB1-0301TPSDPVIIDSHIDQT419
EBF2-YAP1chr825890600chr111020331861089DRB1-0301DPVIIDSHIDQTTTW722
EBF2-YAP1chr825890600chr111020331861089DRB1-0303SDPVIIDSHIDQTTT621
EBF2-YAP1chr825890600chr111020331861089DRB1-0303PSDPVIIDSHIDQTT520
EBF2-YAP1chr825890600chr111020331861089DRB1-0305SDPVIIDSHIDQTTT621
EBF2-YAP1chr825890600chr111020331861089DRB1-0305PSDPVIIDSHIDQTT520
EBF2-YAP1chr825890600chr111020331861089DRB1-0307SDPVIIDSHIDQTTT621
EBF2-YAP1chr825890600chr111020331861089DRB1-0307PSDPVIIDSHIDQTT520
EBF2-YAP1chr825890600chr111020331861089DRB1-0307TPSDPVIIDSHIDQT419
EBF2-YAP1chr825890600chr111020331861089DRB1-0307DPVIIDSHIDQTTTW722
EBF2-YAP1chr825890600chr111020331861089DRB1-0310SDPVIIDSHIDQTTT621
EBF2-YAP1chr825890600chr111020331861089DRB1-0310PSDPVIIDSHIDQTT520
EBF2-YAP1chr825890600chr111020331861089DRB1-0310TPSDPVIIDSHIDQT419
EBF2-YAP1chr825890600chr111020331861089DRB1-0313SDPVIIDSHIDQTTT621
EBF2-YAP1chr825890600chr111020331861089DRB1-0313PSDPVIIDSHIDQTT520
EBF2-YAP1chr825890600chr111020331861089DRB1-0313TPSDPVIIDSHIDQT419
EBF2-YAP1chr825890600chr111020331861089DRB1-0313DPVIIDSHIDQTTTW722
EBF2-YAP1chr825890600chr111020331861089DRB1-0315SDPVIIDSHIDQTTT621
EBF2-YAP1chr825890600chr111020331861089DRB1-0315PSDPVIIDSHIDQTT520
EBF2-YAP1chr825890600chr111020331861089DRB1-0315TPSDPVIIDSHIDQT419
EBF2-YAP1chr825890600chr111020331861089DRB1-0315DPVIIDSHIDQTTTW722
EBF2-YAP1chr825890600chr111020331861089DRB1-0318SDPVIIDSHIDQTTT621
EBF2-YAP1chr825890600chr111020331861089DRB1-0318PSDPVIIDSHIDQTT520
EBF2-YAP1chr825890600chr111020331861089DRB1-0318TPSDPVIIDSHIDQT419
EBF2-YAP1chr825890600chr111020331861089DRB1-0318DPVIIDSHIDQTTTW722
EBF2-YAP1chr825890600chr111020331861089DRB1-0320SDPVIIDSHIDQTTT621
EBF2-YAP1chr825890600chr111020331861089DRB1-0320PSDPVIIDSHIDQTT520
EBF2-YAP1chr825890600chr111020331861089DRB1-0320TPSDPVIIDSHIDQT419
EBF2-YAP1chr825890600chr111020331861089DRB1-0320DPVIIDSHIDQTTTW722
EBF2-YAP1chr825890600chr111020331861089DRB1-0322SDPVIIDSHIDQTTT621
EBF2-YAP1chr825890600chr111020331861089DRB1-0322PSDPVIIDSHIDQTT520
EBF2-YAP1chr825890600chr111020331861089DRB1-0322TPSDPVIIDSHIDQT419
EBF2-YAP1chr825890600chr111020331861089DRB1-0322DPVIIDSHIDQTTTW722
EBF2-YAP1chr825890600chr111020331861089DRB1-0324SDPVIIDSHIDQTTT621
EBF2-YAP1chr825890600chr111020331861089DRB1-0324PSDPVIIDSHIDQTT520
EBF2-YAP1chr825890600chr111020331861089DRB1-0324TPSDPVIIDSHIDQT419
EBF2-YAP1chr825890600chr111020331861089DRB1-0326SDPVIIDSHIDQTTT621
EBF2-YAP1chr825890600chr111020331861089DRB1-0326PSDPVIIDSHIDQTT520
EBF2-YAP1chr825890600chr111020331861089DRB1-0326TPSDPVIIDSHIDQT419
EBF2-YAP1chr825890600chr111020331861089DRB1-0326DPVIIDSHIDQTTTW722
EBF2-YAP1chr825890600chr111020331861089DRB1-0328SDPVIIDSHIDQTTT621
EBF2-YAP1chr825890600chr111020331861089DRB1-0328PSDPVIIDSHIDQTT520
EBF2-YAP1chr825890600chr111020331861089DRB1-0328TPSDPVIIDSHIDQT419
EBF2-YAP1chr825890600chr111020331861089DRB1-0328DPVIIDSHIDQTTTW722
EBF2-YAP1chr825890600chr111020331861089DRB1-0330SDPVIIDSHIDQTTT621
EBF2-YAP1chr825890600chr111020331861089DRB1-0330PSDPVIIDSHIDQTT520
EBF2-YAP1chr825890600chr111020331861089DRB1-0330TPSDPVIIDSHIDQT419
EBF2-YAP1chr825890600chr111020331861089DRB1-0330DPVIIDSHIDQTTTW722
EBF2-YAP1chr825890600chr111020331861089DRB1-0332SDPVIIDSHIDQTTT621
EBF2-YAP1chr825890600chr111020331861089DRB1-0332PSDPVIIDSHIDQTT520
EBF2-YAP1chr825890600chr111020331861089DRB1-0332TPSDPVIIDSHIDQT419
EBF2-YAP1chr825890600chr111020331861089DRB1-0332DPVIIDSHIDQTTTW722
EBF2-YAP1chr825890600chr111020331861089DRB1-0334SDPVIIDSHIDQTTT621
EBF2-YAP1chr825890600chr111020331861089DRB1-0334PSDPVIIDSHIDQTT520
EBF2-YAP1chr825890600chr111020331861089DRB1-0334TPSDPVIIDSHIDQT419
EBF2-YAP1chr825890600chr111020331861089DRB1-0334DPVIIDSHIDQTTTW722
EBF2-YAP1chr825890600chr111020331861089DRB1-0336SDPVIIDSHIDQTTT621
EBF2-YAP1chr825890600chr111020331861089DRB1-0336PSDPVIIDSHIDQTT520
EBF2-YAP1chr825890600chr111020331861089DRB1-0336TPSDPVIIDSHIDQT419
EBF2-YAP1chr825890600chr111020331861089DRB1-0336DPVIIDSHIDQTTTW722
EBF2-YAP1chr825890600chr111020331861089DRB1-0340SDPVIIDSHIDQTTT621
EBF2-YAP1chr825890600chr111020331861089DRB1-0340PSDPVIIDSHIDQTT520
EBF2-YAP1chr825890600chr111020331861089DRB1-0342SDPVIIDSHIDQTTT621
EBF2-YAP1chr825890600chr111020331861089DRB1-0342PSDPVIIDSHIDQTT520
EBF2-YAP1chr825890600chr111020331861089DRB1-0342TPSDPVIIDSHIDQT419
EBF2-YAP1chr825890600chr111020331861089DRB1-0344SDPVIIDSHIDQTTT621
EBF2-YAP1chr825890600chr111020331861089DRB1-0344PSDPVIIDSHIDQTT520
EBF2-YAP1chr825890600chr111020331861089DRB1-0344TPSDPVIIDSHIDQT419
EBF2-YAP1chr825890600chr111020331861089DRB1-0344DPVIIDSHIDQTTTW722
EBF2-YAP1chr825890600chr111020331861089DRB1-0346SDPVIIDSHIDQTTT621
EBF2-YAP1chr825890600chr111020331861089DRB1-0346PSDPVIIDSHIDQTT520
EBF2-YAP1chr825890600chr111020331861089DRB1-0346TPSDPVIIDSHIDQT419
EBF2-YAP1chr825890600chr111020331861089DRB1-0346DPVIIDSHIDQTTTW722
EBF2-YAP1chr825890600chr111020331861089DRB1-0348SDPVIIDSHIDQTTT621
EBF2-YAP1chr825890600chr111020331861089DRB1-0348PSDPVIIDSHIDQTT520
EBF2-YAP1chr825890600chr111020331861089DRB1-0348TPSDPVIIDSHIDQT419
EBF2-YAP1chr825890600chr111020331861089DRB1-0348DPVIIDSHIDQTTTW722
EBF2-YAP1chr825890600chr111020331861089DRB1-0350SDPVIIDSHIDQTTT621
EBF2-YAP1chr825890600chr111020331861089DRB1-0350PSDPVIIDSHIDQTT520
EBF2-YAP1chr825890600chr111020331861089DRB1-0350TPSDPVIIDSHIDQT419
EBF2-YAP1chr825890600chr111020331861089DRB1-0350DPVIIDSHIDQTTTW722
EBF2-YAP1chr825890600chr111020331861089DRB1-0352SDPVIIDSHIDQTTT621
EBF2-YAP1chr825890600chr111020331861089DRB1-0352PSDPVIIDSHIDQTT520
EBF2-YAP1chr825890600chr111020331861089DRB1-0352TPSDPVIIDSHIDQT419
EBF2-YAP1chr825890600chr111020331861089DRB1-0352DPVIIDSHIDQTTTW722
EBF2-YAP1chr825890600chr111020331861089DRB1-0354SDPVIIDSHIDQTTT621
EBF2-YAP1chr825890600chr111020331861089DRB1-0354PSDPVIIDSHIDQTT520
EBF2-YAP1chr825890600chr111020331861089DRB1-0354TPSDPVIIDSHIDQT419
EBF2-YAP1chr825890600chr111020331861089DRB1-0354DPVIIDSHIDQTTTW722
EBF2-YAP1chr825890600chr111020331861089DRB1-0411IDSHIDQTTTWQDPR1126
EBF2-YAP1chr825890600chr111020331861089DRB1-0466SDPVIIDSHIDQTTT621
EBF2-YAP1chr825890600chr111020331861089DRB1-0466PSDPVIIDSHIDQTT520
EBF2-YAP1chr825890600chr111020331861089DRB1-0467IDSHIDQTTTWQDPR1126
EBF2-YAP1chr825890600chr111020331861089DRB1-0491IDSHIDQTTTWQDPR1126
EBF2-YAP1chr825890600chr111020331861089DRB1-1107SDPVIIDSHIDQTTT621
EBF2-YAP1chr825890600chr111020331861089DRB1-1107PSDPVIIDSHIDQTT520
EBF2-YAP1chr825890600chr111020331861089DRB1-1107TPSDPVIIDSHIDQT419
EBF2-YAP1chr825890600chr111020331861089DRB1-1107DPVIIDSHIDQTTTW722
EBF2-YAP1chr825890600chr111020331861089DRB1-1179SDPVIIDSHIDQTTT621
EBF2-YAP1chr825890600chr111020331861089DRB1-1394SDPVIIDSHIDQTTT621
EBF2-YAP1chr825890600chr111020331861089DRB1-1394PSDPVIIDSHIDQTT520
EBF2-YAP1chr825890600chr111020331861089DRB1-1410IDSHIDQTTTWQDPR1126
EBF2-YAP1chr825890600chr111020331861089DRB1-1421SDPVIIDSHIDQTTT621
EBF2-YAP1chr825890600chr111020331861089DRB1-1421PSDPVIIDSHIDQTT520
EBF2-YAP1chr825890600chr111020331861089DRB1-1476SDPVIIDSHIDQTTT621
EBF2-YAP1chr825890600chr111020331861089DRB1-1476PSDPVIIDSHIDQTT520
EBF2-YAP1chr825890600chr111020331861089DRB1-1476TPSDPVIIDSHIDQT419
EBF2-YAP1chr825890600chr111020331861089DRB1-1479SDPVIIDSHIDQTTT621
EBF2-YAP1chr825890600chr111020331861089DRB1-1479PSDPVIIDSHIDQTT520
EBF2-YAP1chr825890600chr111020331861089DRB1-1479TPSDPVIIDSHIDQT419
EBF2-YAP1chr825890600chr111020331861089DRB4-0101SDPVIIDSHIDQTTT621
EBF2-YAP1chr825890600chr111020331861089DRB4-0101DPVIIDSHIDQTTTW722
EBF2-YAP1chr825890600chr111020331861089DRB4-0101PSDPVIIDSHIDQTT520
EBF2-YAP1chr825890600chr111020331861089DRB4-0103SDPVIIDSHIDQTTT621
EBF2-YAP1chr825890600chr111020331861089DRB4-0103DPVIIDSHIDQTTTW722
EBF2-YAP1chr825890600chr111020331861089DRB4-0103PSDPVIIDSHIDQTT520
EBF2-YAP1chr825890600chr111020331861089DRB4-0104SDPVIIDSHIDQTTT621
EBF2-YAP1chr825890600chr111020331861089DRB4-0104DPVIIDSHIDQTTTW722
EBF2-YAP1chr825890600chr111020331861089DRB4-0104PSDPVIIDSHIDQTT520
EBF2-YAP1chr825890600chr111020331861089DRB4-0106SDPVIIDSHIDQTTT621
EBF2-YAP1chr825890600chr111020331861089DRB4-0106DPVIIDSHIDQTTTW722
EBF2-YAP1chr825890600chr111020331861089DRB4-0106PSDPVIIDSHIDQTT520
EBF2-YAP1chr825890600chr111020331861089DRB4-0107SDPVIIDSHIDQTTT621
EBF2-YAP1chr825890600chr111020331861089DRB4-0107DPVIIDSHIDQTTTW722
EBF2-YAP1chr825890600chr111020331861089DRB4-0107PSDPVIIDSHIDQTT520
EBF2-YAP1chr825890600chr111020331861089DRB4-0108SDPVIIDSHIDQTTT621
EBF2-YAP1chr825890600chr111020331861089DRB4-0108DPVIIDSHIDQTTTW722
EBF2-YAP1chr825890600chr111020331861089DRB4-0108PSDPVIIDSHIDQTT520

Top

Fusion breakpoint peptide structures of EBF2-YAP1

check button3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.
File nameBPseqHgeneTgeneHchrHbpTchrTbpAAlen
8478SDPVIIDSHIDQTTEBF2YAP1chr825890600chr111020331861089

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of EBF2-YAP1

check buttonVirtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.
HLA allelePDB IDFile nameBPseqDocking scoreGlide score
HLA-B14:023BVN8478SDPVIIDSHIDQTT-7.15543-7.26883
HLA-B14:023BVN8478SDPVIIDSHIDQTT-4.77435-5.80965
HLA-B52:013W398478SDPVIIDSHIDQTT-6.80875-6.92215
HLA-B52:013W398478SDPVIIDSHIDQTT-4.20386-5.23916
HLA-A11:014UQ28478SDPVIIDSHIDQTT-7.5194-8.5547
HLA-A11:014UQ28478SDPVIIDSHIDQTT-6.9601-7.0735
HLA-A24:025HGA8478SDPVIIDSHIDQTT-7.52403-7.63743
HLA-A24:025HGA8478SDPVIIDSHIDQTT-5.82433-6.85963
HLA-B27:056PYJ8478SDPVIIDSHIDQTT-3.28285-4.31815
HLA-B44:053DX88478SDPVIIDSHIDQTT-5.91172-6.94702
HLA-B44:053DX88478SDPVIIDSHIDQTT-4.24346-4.35686

Top

Vaccine Design for the FusionNeoAntigens of EBF2-YAP1

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptide sequenceFusionNeoAntigen RNA sequence
EBF2-YAP1chr825890600chr111020331861122IDSHIDQTTTWTGACAGTCACATCGATCAGACAACAACATGGCA
EBF2-YAP1chr825890600chr111020331861222DSHIDQTTTWCAGTCACATCGATCAGACAACAACATGGCA

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptideFusionNEoAntigen RNA sequence
EBF2-YAP1chr825890600chr111020331861126IDSHIDQTTTWQDPRTGACAGTCACATCGATCAGACAACAACATGGCAGGACCCCAGGAA
EBF2-YAP1chr825890600chr11102033186419TPSDPVIIDSHIDQTTCCATCGGACCCAGTCATAATTGACAGTCACATCGATCAGACAAC
EBF2-YAP1chr825890600chr11102033186520PSDPVIIDSHIDQTTATCGGACCCAGTCATAATTGACAGTCACATCGATCAGACAACAAC
EBF2-YAP1chr825890600chr11102033186621SDPVIIDSHIDQTTTGGACCCAGTCATAATTGACAGTCACATCGATCAGACAACAACATG
EBF2-YAP1chr825890600chr11102033186722DPVIIDSHIDQTTTWCCCAGTCATAATTGACAGTCACATCGATCAGACAACAACATGGCA

Top

Information of the samples that have these potential fusion neoantigens of EBF2-YAP1

check button These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.
Cancer typeFusion geneHchrHbpHenstTchrTbpTenstSample
Non-CancerEBF2-YAP1chr825890600ENST00000520164chr11102033186ENST00000282441TCGA-BH-A0BC-11A

Top

Potential target of CAR-T therapy development for EBF2-YAP1

check button Predicted 3D structure. We used RoseTTAFold.

check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features


* Minus value of BPloci means that the break point is located before the CDS.
- In-frame and retained 'Transmembrane'.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note

check button Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.
HgeneHchrHbpHenstTgeneTchrTbpTenstDeepLoc result

Top

Related Drugs to EBF2-YAP1

check button Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDrugSourcePMID

Top

Related Diseases to EBF2-YAP1

check button Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDiseaseSourcePMID

check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource